Enveric Biosciences, Inc.
For the period ended Dec 31, 2025. Filed Mar 27, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 27, 2026
ENVB$1.44+1.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| As of December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| ASSETS | ||
| Current assets: | ||
| Cash | $4,677,491 | $2,241,026 |
| Prepaid expenses and other current assets | 259,216 | 493,558 |
| Total current assets | 4,936,707 | 2,734,584 |
| Other assets: | ||
| Property and equipment, net | 159,234 | 305,777 |
| Intangible assets, net | — | 42,182 |
| Total other assets | 159,234 | 347,959 |
| Total assets | $5,095,941 | $3,082,543 |
| LIABILITIES, MEZZANINE EQUITY, AND SHAREHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $581,020 | $521,747 |
| Due to related parties | 99,875 | 232,891 |
| Accrued expenses and other current liabilities | 237,505 | 735,098 |
| Total current liabilities | 918,400 | 1,489,736 |
| Commitments and contingencies (Note 9) | ||
| Mezzanine equity | ||
| Series C redeemable preferred stock, $0.01 par value, 100,000 shares authorized, and 0 shares issued and outstanding as of December 31, 2025 and 2024, respectively | — | — |
| Total mezzanine equity | — | — |
| Shareholders’ equity | ||
| Preferred stock, $0.01 par value, 20,000,000 shares authorized; Series B preferred stock, $0.01 par value, 3,600,000 shares authorized, 0 shares issued and outstanding as of December 31, 2025 and 2024, respectively | — | — |
| Common stock, $0.01 par value, 100,000,000 shares authorized, 1,061,533 and 56,501 shares issued and outstanding as of December 31, 2025 and 2024, respectively | 10,615 | 565 |
| Additional paid-in capital | 119,593,456 | 108,261,264 |
| Accumulated deficit | (114,846,492) | (106,074,505) |
| Accumulated other comprehensive loss | (580,038) | (594,517) |
| Total shareholders’ equity | 4,177,541 | 1,592,807 |
| Total liabilities, mezzanine equity, and shareholders’ equity | $5,095,941 | $3,082,543 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.